Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ENA-78 CRISPR/Cas9 KO Plasmid (h): sc-405834
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ENA-78 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ENA-78 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ENA-78 Antibody (YZ-14): sc-73931
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ENA-78 CRISPR/Cas9 KO Plasmid (h) | sc-405834 | 20 µg | $397.00 |
Overview
CXCL5 encodes epithelial neutrophil-activating peptide 78 (ENA-78), a CXC chemokine secreted by epithelial and stromal cells that directs neutrophil chemotaxis and activation via CXCR2 signaling. ENA-78 contributes to inflammatory cell recruitment, modulation of endothelial behavior, and coordination of tissue responses through pathways linked to MAPK and NF-κB-regulated transcriptional programs. Dysregulated CXCL5 expression has been associated with chronic inflammatory microenvironments, aberrant leukocyte trafficking, and tumor-associated inflammation in multiple tissue contexts. As a mediator of innate immune signaling, CXCL5 is frequently studied in models of mucosal inflammation, wound responses, and cytokine network crosstalk.
ENA-78 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CXCL5 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CXCL5 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CXCL5 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ENA-78 protein expression.
This CRISPR knockout system enables efficient generation of CXCL5-deficient cell models for investigation of ENA-78 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CXCL5 exon(s) critical for ENA-78 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CXCL5 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ENA-78 CRISPR/Cas9 KO Plasmid (h) and ENA-78 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CXCL5 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ENA-78 HDR Plasmid (h) and ENA-78 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CXCL5 homology arms to support homology-directed repair at defined CXCL5 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.